RMD · Categories · Downgrades
RMD - Analyst downgrades
ResMed Inc. (RMD) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for RMD
- ResMed downgraded by Canaccord GenuityCanaccord Genuity downgraded ResMed from Buy to Hold
- ResMed downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $234.00
- ResMed downgraded by Citigroup with a new price targetCitigroup downgraded ResMed from Buy to Neutral and set a new price target of $235.00
- ResMed downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded ResMed from Overweight to Equal-Weight and set a new price target of $230.00
- ResMed downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded ResMed from Outperform to Neutral and set a new price target of $275.00
- ResMed downgraded by Wolfe Research with a new price targetWolfe Research downgraded ResMed from Peer Perform to Underperform and set a new price target of $180.00
- ResMed downgraded by NeedhamNeedham downgraded ResMed from Buy to Hold
- ResMed downgraded by OppenheimerOppenheimer downgraded ResMed from Outperform to Perform
- ResMed downgraded by CitigroupCitigroup downgraded ResMed from Buy to Neutral
- ResMed downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $202.00 from $273.00 previously
- ResMed downgraded by Wolfe ResearchWolfe Research downgraded ResMed from Outperform to Peer Perform
- ResMed downgraded by UBS with a new price targetUBS downgraded ResMed from Buy to Neutral and set a new price target of $170.00 from $265.00 previously
- ResMed downgraded by CitigroupCitigroup downgraded ResMed from Buy to Neutral
- ResMed downgraded by CLSACLSA downgraded ResMed from Buy to Outperform
- ResMed downgraded by JP MorganJP Morgan downgraded ResMed from Overweight to Neutral
- ResMed downgraded by CitigroupCitigroup downgraded ResMed from Buy to Neutral
- ResMed downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $252.00 from $246.00 previously
- ResMed downgraded by CLSACLSA downgraded ResMed from Outperform to Sell
- ResMed downgraded by NeedhamNeedham downgraded ResMed from Buy to Hold
- ResMed downgraded by JP Morgan with a new price targetJP Morgan downgraded ResMed from Overweight to Neutral and set a new price target of $246.00 from $245.00 previously
- ResMed downgraded by CitigroupCitigroup downgraded ResMed from Buy to Neutral
- ResMed downgraded by B of A Securities with a new price targetB of A Securities downgraded ResMed from Neutral to Underperform and set a new price target of $221.00 from $216.00 previously
- ResMed downgraded by CitigroupCitigroup downgraded ResMed from Buy to Neutral
Other RMD categories
Is something on this page wrong? Request a change